Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283397788> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4283397788 endingPage "860" @default.
- W4283397788 startingPage "859" @default.
- W4283397788 abstract "Background: Thromboprophylaxis is routinely used with lenalidomide-based regimens in multiple myeloma because of a substantial risk of venous thromboembolism (VTE). Aspirin is one of the most common thromboprophylaxis agent but also increases bleeding complications.Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action which can mitigate the risk of higher incidence of VTE without an observable increase in bleeding rates.However, little is known about the incidence of VTE in lenalidomide-based regimens with rivaroxaban thromboprophylaxis. Aims: The purpose of our study was to compare of venous thromboembolism incidence in multiple myeloma patients receiving lenalidomide-based regimen with rivaroxaban or aspirin thromboprophylaxis. Methods: We conducted a single-centre retrospective study designed to assess the rates of VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT), in MM patients receiving lenalidomide-based regimen with aspirin or rivaroxaban thromboprophylaxis.A total of 130 patients who were not anticoagulated for other clinical indications and received at least 1 cycle of lenalidomide-based regimen between January 2015 and December 2021 were included. Clinical bleeding events after treatment were also important indicators in our study. Results: The incidence of venous thromboembolism in the rivaroxaban group was significantly lower than that in the aspirin prevention group (P<0.05). The incidence of bleeding in the rivaroxaban group was also lower than that in the aspirin prevention group,but there was no statistical significance(P﹥0.05). Table II. - Analysis of VTE and Bleeding. Regimen + prophylaxis R-based regimens+ASA（n=84） R-based regimens+XA（n=46） P-value VTE 13（15.5%） 1（2.2%） 0.041 Bleeding 6（7.1%） 0 0.081 ASA, aspirin; XA, rivaroxaban; VTE, venous thromboembolism. Image:Summary/Conclusion: In this pilot study, we found that rivaroxaban was safe and well-tolerated as the primary preventive measure for venous thromboembolism in patients with multiple myeloma receiving lenalidomide-based regimen. However, these findings warrant further investigation in a larger randomized study to be validated." @default.
- W4283397788 created "2022-06-25" @default.
- W4283397788 creator A5006548866 @default.
- W4283397788 creator A5010616010 @default.
- W4283397788 creator A5013603274 @default.
- W4283397788 creator A5041366719 @default.
- W4283397788 creator A5051263131 @default.
- W4283397788 creator A5060557052 @default.
- W4283397788 creator A5074643507 @default.
- W4283397788 creator A5077764073 @default.
- W4283397788 creator A5082534076 @default.
- W4283397788 date "2022-06-01" @default.
- W4283397788 modified "2023-10-16" @default.
- W4283397788 title "P969: COMPARISON OF VENOUS THROMBOEMBOLISM INCIDENCE IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE-BASED REGIMENS WITH RIVAROXABAN OR ASPIRIN THROMBOPROPHYLAXIS" @default.
- W4283397788 doi "https://doi.org/10.1097/01.hs9.0000846744.38970.75" @default.
- W4283397788 hasPublicationYear "2022" @default.
- W4283397788 type Work @default.
- W4283397788 citedByCount "1" @default.
- W4283397788 countsByYear W42833977882023 @default.
- W4283397788 crossrefType "journal-article" @default.
- W4283397788 hasAuthorship W4283397788A5006548866 @default.
- W4283397788 hasAuthorship W4283397788A5010616010 @default.
- W4283397788 hasAuthorship W4283397788A5013603274 @default.
- W4283397788 hasAuthorship W4283397788A5041366719 @default.
- W4283397788 hasAuthorship W4283397788A5051263131 @default.
- W4283397788 hasAuthorship W4283397788A5060557052 @default.
- W4283397788 hasAuthorship W4283397788A5074643507 @default.
- W4283397788 hasAuthorship W4283397788A5077764073 @default.
- W4283397788 hasAuthorship W4283397788A5082534076 @default.
- W4283397788 hasBestOaLocation W42833977881 @default.
- W4283397788 hasConcept C120665830 @default.
- W4283397788 hasConcept C121332964 @default.
- W4283397788 hasConcept C126322002 @default.
- W4283397788 hasConcept C141071460 @default.
- W4283397788 hasConcept C2776063141 @default.
- W4283397788 hasConcept C2776265017 @default.
- W4283397788 hasConcept C2776301958 @default.
- W4283397788 hasConcept C2776364478 @default.
- W4283397788 hasConcept C2777628954 @default.
- W4283397788 hasConcept C2778661090 @default.
- W4283397788 hasConcept C2779161974 @default.
- W4283397788 hasConcept C2779609412 @default.
- W4283397788 hasConcept C2780011451 @default.
- W4283397788 hasConcept C2780868729 @default.
- W4283397788 hasConcept C2781413609 @default.
- W4283397788 hasConcept C61511704 @default.
- W4283397788 hasConcept C71924100 @default.
- W4283397788 hasConceptScore W4283397788C120665830 @default.
- W4283397788 hasConceptScore W4283397788C121332964 @default.
- W4283397788 hasConceptScore W4283397788C126322002 @default.
- W4283397788 hasConceptScore W4283397788C141071460 @default.
- W4283397788 hasConceptScore W4283397788C2776063141 @default.
- W4283397788 hasConceptScore W4283397788C2776265017 @default.
- W4283397788 hasConceptScore W4283397788C2776301958 @default.
- W4283397788 hasConceptScore W4283397788C2776364478 @default.
- W4283397788 hasConceptScore W4283397788C2777628954 @default.
- W4283397788 hasConceptScore W4283397788C2778661090 @default.
- W4283397788 hasConceptScore W4283397788C2779161974 @default.
- W4283397788 hasConceptScore W4283397788C2779609412 @default.
- W4283397788 hasConceptScore W4283397788C2780011451 @default.
- W4283397788 hasConceptScore W4283397788C2780868729 @default.
- W4283397788 hasConceptScore W4283397788C2781413609 @default.
- W4283397788 hasConceptScore W4283397788C61511704 @default.
- W4283397788 hasConceptScore W4283397788C71924100 @default.
- W4283397788 hasLocation W42833977881 @default.
- W4283397788 hasLocation W42833977882 @default.
- W4283397788 hasLocation W42833977883 @default.
- W4283397788 hasOpenAccess W4283397788 @default.
- W4283397788 hasPrimaryLocation W42833977881 @default.
- W4283397788 hasRelatedWork W1966357810 @default.
- W4283397788 hasRelatedWork W1974135782 @default.
- W4283397788 hasRelatedWork W1980068016 @default.
- W4283397788 hasRelatedWork W2022036807 @default.
- W4283397788 hasRelatedWork W2030475312 @default.
- W4283397788 hasRelatedWork W2041042375 @default.
- W4283397788 hasRelatedWork W2058009067 @default.
- W4283397788 hasRelatedWork W2462844398 @default.
- W4283397788 hasRelatedWork W2979889274 @default.
- W4283397788 hasRelatedWork W3042537788 @default.
- W4283397788 hasVolume "6" @default.
- W4283397788 isParatext "false" @default.
- W4283397788 isRetracted "false" @default.
- W4283397788 workType "article" @default.